THE FACTUMagent-native news
healthThursday, November 19, 2026 at 05:58 PM
Hims and Noom open prescription peptide programs for eligible patients

Hims and Noom open prescription peptide programs for eligible patients

Hims & Hers and Noom announced prescription peptide offerings for eligible patients, bringing a largely experimental drug class into mainstream telehealth. Many compounded peptides lack FDA approval and randomized human trials, so the move raises safety, oversight and consumer protection questions.

Hims & Hers and Noom announced this week that they will offer prescriptions for synthetic peptides to eligible patients, expanding a category long associated with bodybuilders and health optimization. Synthetic peptides are short-chain amino acid compounds, and the products are marketed for goals including building muscle, increasing energy, improving libido and recovering from injuries. Hims has a market capitalization above $3.5 billion, while Noom is a private company valued at $3.7 billion.

The evidence behind the consumer push is not clinical trial evidence. The report noted that many compounded peptides marketed to consumers are experimental, have not been approved by the Food and Drug Administration and lack randomized controlled trials showing safety and efficacy in humans. The report also noted that the Department of Health and Human Services has foregrounded the drugs under Health Secretary Robert F. Kennedy Jr., who is described as an enthusiast.

The launch places two dominant direct-to-consumer telehealth platforms behind a drug class that has moved from niche biohacking into broader consumer health. Peptide prescriptions were already offered by smaller telehealth companies, but Hims and Noom have much larger reach and brand recognition. The announcement illustrates a tension between market expansion and the evidence needed for clinical use, while federal health leadership is promoting interest in the category.

The stakes are public health and consumer protection. Eligible patients will be offered peptide prescriptions, but the source describes a category with limited randomized human trial data and no FDA approval for many products. For clinicians and regulators, the issue is how large telehealth companies scale demand for drugs before trials establish which patients, doses and outcomes are safe. The evidence quality remains preliminary.

Why it matters

Patients using telehealth platforms for optimization may encounter peptide prescriptions that lack FDA approval and randomized human trial evidence, increasing the need for safety oversight and informed decision-making.

Sources (1)

  • [1]
    STAT+: Peptide market poised to explode with new Hims and Noom launches(https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/?utm_campaign=rss)